Xavier Becerra is Biden’s pick for HHS (Health and Human Services). Earlier this week, he took questions from Republican lawmakers, covering a wide range of topics. Probing questions related to health insurance coverage were thoroughly covered. However, the GOP avoided questions related to drug […]
Aetion’s Take on RWE Expansion in Europe
Aetion’s Ashley Jaska, Vice President of Science, and Nicholas Deltour, Vice President of Real-World Solutions, offered their insight into how RWE (real world evidence) might progress in Europe. For years, RWD (real world data) has been used by pharmaceutical companies to make safety calls. Now, […]
Storage a Major Challenge in Genomics Tools for Precision Medicine
Genomics tools are driving progress in precision medicine. These tools, such as next generation sequencing (NGS) technologies, allow for large amounts of data to be collected and analyzed per person. However, storing the exponentially increasing amounts of data remains a simple yet difficult problem […]
Prescription Drugs Only One Piece of High Healthcare Costs–Look to Provider Cost
Dr. Anupam Jena, an associate professor of healthcare policy at Harvard Medical School and doctor at Massachusetts General Hospital, shares his thoughts on the high price of American medicine. He notes that over 30% of national health expenditures go to hospital care while another 20% come from […]
California and New York Newest States Seeking to Create Their Own Contracts With Medicaid
A growing number of states have decided to form their own contracts with Medicaid. Most recently, California and New York announced their plans to negotiate their own rates. This trend is expected to continue—other states including Tennessee, West Virginia, Wisconsin, Missouri, and North Dakota have […]
ISMPP Releases Results of Poll on Marketing Scenario
The ISMPP recently published the results of a poll asking respondents how they might respond to a scenario where a marketing colleague seeks to sit in on a strategic data meeting with the respondent’s medical colleagues. Nearly 75% of the 115 participants decided to maintain their meeting format, […]
2021 Healthcare Predictions As Democrats Hold House, Senate, Presidential Office
Now that Democrats hold control of the House of Representatives, the Senate, and Biden has been elected president, healthcare is expected to be one major area of focus. A new stimulus bill is anticipated along with a nationwide vaccine push. A new report discusses which healthcare policies will […]
Register Today for Virtual ISPOR 2021 Conference on HEOR, HTAs, and RWD
ISPOR will host its yearly conference on HEOR (health economics and outcomes research) virtually, from May 17-20. The theme of this year’s conference is: HEOR: Evolving for Tomorrow’s Challenges. Register today to attend important sessions on RWD (real world data), study design, HTAs (health […]
A Conversation with Gilead Leader on Impact of RWE in Drug Development
Dr. Diana Brainard, Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, provides her thoughts on the role of RWE (real world evidence) during the COVID-19 pandemic and how it’s forever changed the drug development landscape. Thanks to RWE, Gilead has been able to analyze […]
Understanding the Spectrum of Low-Value Care and Economic Implications
In a recent study, researchers compared over one thousand low-value care recommendations from five US healthcare organizations (USPSTF, ACP, ACC/AHA, ASCO, and the Choosing Wisely Initiative). They sought to assess the clinical benefits and economic value of these recommendations, noting a large […]
The Case for Prescription Drug Price Transparency: Listen to Patients and Providers
Although recent regulations require healthcare systems to provide pricing information, there is no standardized method to do so. With these changes in transparency come new technologies that allow providers to access real-time pricing data, allowing for easily accessible information. Patients are […]
The US FDA Has a Different Rubric for Cancer Drug Approval Than the UK and Canada
Different regulatory bodies have different criteria when it comes to drug approval, especially in the case of cancer drugs. The US FDA tends to be accepting of less-than-certain outcomes and prefers to accelerate cancer drug approvals. However, the use of surrogate markers is not always associated […]
Sarepta’s New Treatment for Duchenne Muscular Dystrophy Approved by FDA, $1 Million Yearly Cost Despite Lack of Confirmation Studies
Sarepta Therapeutics has created a third drug for use in Duchenne Muscular Dystrophy (DMD), termed Amondys 45. It recently received approval from the FDA. The pharma company’s three DMD drugs: Amondys 45, Exondys 51, and Vvondys 53, will reach approximately a third of patients with DMD. However, […]
How Will Emphasis on Patient Centricity and ICER Influence Payer Decisions?
The 21st Century Cures Act, as well as FDA guidelines, are putting a spotlight on patient centricity—from drug development to patient care. In a recent report, ICON surveyed top payers in the US to determine how PROs impact decisions across this spectrum, including predictions regarding future […]
Swedish Scientist Faces Backlash Over COVID-19 Research, Sweden to Strengthen Academic Freedom Laws
Jonas Ludvigsson, a professor of clinical epidemiology at the Karolinska Institute and a pediatrician at Örebro University Hospital, examined the incidence of COVID-19 in children. He noted relatively low rates of severe disease in children. His peer-reviewed publication was seen as in direct […]
Pricing Experts Offer Insight Into Use of Advanced Analytics, Note 85% of Companies Lack Sufficient Data or Detailed Pricing Information
85% of interviewed companies lack sufficient data, price quality, or price transparency information to be able to properly apply advanced analytics. Experts in the industry have recognized the potential applications of advanced analytics, but understanding the point at which, and how, to utilize […]
2021 Global Medical Affairs Outsourcing Market Research Report Details 2028 Outlook
HealthCare Intelligence has released a report analyzing worldwide trends relating to healthcare outsourcing markets using primary and secondary methods along with SWOT analysis and Porter’s Five Forces Framework. Predicted trends for 2021 are described in detail, along with predictions for 2028. […]
New Bills Propose High Taxes for Unjustified Drug Price Increases
Legislators in Washington and Hawaii have introduced bills aimed at drug price increases by pharmaceutical companies. Should these bills be passed, price increases without sufficient clinical evidence would bring large penalties upon the pharma companies. These bills, among others aimed at limiting […]
Aetna Return to ACA Exchanges Reflects Industry-Wide Trend Amid COVID-19 Relief Package Boost
The Aetna insurance division of the CVS Health Corp. will return to the ACA (Affordable Care Act) exchanges in 2022. Experts see the move as a sign that the individual insurance market is becoming increasingly appealing for payers. This Aetna move is expected to be one of many similar shifts in the […]
A Discussion with Paul Perreault of CSL Limited on COVID-19
Paul Perreault is CEO and Managing Director of CSL Limited, a top three global biotech company. He was invited to share his insights regarding COVID-19 and how his company has been able to adjust to the pandemic. CSL helped to establish the CoVIg-19 Plasma Alliance to develop immune therapies and […]
Will ‘All of Us’ Bring Positive Change to Research?
“All of Us” is the $1.5 billion initiative led by the federal government with the purpose of collecting health data from diverse backgrounds. It’s considered as an important step forward in precision medicine—for all backgrounds. At the same time, it may also have far-reaching impacts in driving […]
Google Reveals Care Studio Tool for Providers
Google has piloted a new search tool for electronic medical records called Care Studio. In the trial phase, around 250 clinicians will be able to use it. The tool will allow providers to save time when sorting through patient records. Over a year ago, Google attempted a partnership with the hospital […]
IBM’s Watson AI Technology Falls Short of Potential
A decade ago, IBM (International Business Machine Corporation) used its AI (artificial intelligence) technology system termed Watson to beat people in the show “Jeopardy!” This showcase led to much speculation on the use of AI in other sectors, especially healthcare. Now, IBM is considering selling […]
NBER Releases Cost-Sharing Report: Drug Price Increases Associated With Increased Mortality
The National Bureau of Economic Research (NBER) has released a report on how cost-sharing affects patient care. The authors found that a price increase of approximately $10.40 per drug leads to a 22.6 % decrease in use of prescription drugs. The price increase also corresponds to a significant […]
Datavant Seeks to Improve Data Sharing
Datavant seeks to streamline data sharing across platforms while maintaining privacy. Datavant has recently announced partnerships with specialty hub providers, including IntegriChain, PRECISIONxtract, and EVERSANA. Unlike other platforms, Datavant provides extensive patient data, without disclosing […]
Epidemiologists Build COVID-19 Data Platform—With Help From Google
Epidemiologists Build COVID-19 Data Platform—With Help From Google
In January of 2020, Samuel Scarpino, director of the Emergent Epidemics Lab at Northeastern University, started inputting data in a globally-shared worksheet. This worksheet was the basis for a new website: Global.health. Anonymized records of five million COVID-19 cases from more than 100 countries […]
CDC Introduces VaccineFinder
In an effort to provide the public with information regarding COVID-19 vaccine availability, the CDC has released VaccineFinder, an online tool that allows users to find a COVID-19 vaccine close to their zip code. Users can select either the Moderna or Pfizer-BioNTech vaccine, check availability, […]
Republicans Criticize Biden’s Health Secretary Pick
Biden’s pick for health secretary, Xavier Becerra, currently serving as attorney general in California, has not been welcomed by Republican Senators. The main criticism centers around his stance on pharma: Becerra isn’t supportive enough. “The attack on Xavier Becerra, California’s attorney […]
Aetion Vice President of Growth and Strategic Partnerships Discusses RWE
Ian Rentsch recently became Vice President of Growth and Strategic Partnerships at Aetion. He previously held roles in clinical research and development and in global RWD (real world data) companies. In a recent discussion, he offers his opinions regarding the state of RWE (real world evidence) and […]
[Workshop] RWE in Regulatory Decision-Making Processes
A recent workshop focusing on RWE (real world evidence) explored the role in observational studies in determining drug effectiveness and in seeking FDA approval. Speakers discuss challenges in using RWE and how to identify and address gaps in knowledge. The two-day online workshop took place in […]
